LCWP
VRTX icon

Legacy Capital Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Legacy Capital Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$987K Buy
1,988
+87
+5% +$38.6K 0.19% 106
2026
Q1 		$849K Buy
1,901
+174
+10% +$81.1K 0.17% 123
2025
Q4 		$783K Buy
1,727
+224
+15% +$96.5K 0.17% 130
2025
Q3 		$589K Buy
1,503
+503
+50% +$210K 0.13% 174
2025
Q2 		$445K Buy
1,000
+50
+5% +$23K 0.1% 220
2025
Q1 		$461K Buy
950
+62
+7% +$28.9K 0.11% 198
2024
Q4 		$358K Sell
888
-199
-18% -$92.2K 0.09% 238
2024
Q3 		$506K Buy
1,087
+501
+85% +$241K 0.1% 193
2024
Q2 		$275K Buy
+586
New +$254K 0.07% 255

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Legacy Capital Wealth Partners's VRTX Position: Q2 2026 in Review

Legacy Capital Wealth Partners increased its Vertex Pharmaceuticals (VRTX) stake by 4.6% in Q2 2026, buying an estimated $38.6K and bringing the position to 1,988 shares worth $987K. The position accounts for 0.19% of the portfolio, ranked #106.

Legacy Capital Wealth Partners first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Legacy Capital Wealth Partners held 1,988 shares of Vertex Pharmaceuticals worth $987K as of Q2 2026.
  • Legacy Capital Wealth Partners bought 87 Vertex Pharmaceuticals shares in Q2 2026, an estimated $38.6K.
  • Vertex Pharmaceuticals made up 0.19% of Legacy Capital Wealth Partners's portfolio in Q2 2026, its #106 holding.
  • Legacy Capital Wealth Partners first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Legacy Capital Wealth Partners's 13F filing for Q2 2026, filed 12 Aug 2026.